Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog

Results of a double- blind, placebo-controlled randomized study

R. Alam, A. Dejarnatt, S. Stafford, P. A. Forsythe, D. Kumar, J. A. Grant

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The objective of this study was to investigate the effect of misoprostol on allergen-induced cutaneous immediate- and late-phase allergic reactions in a double-blind placebo-controlled randomized study. We also studied the mechanism of antiallergic effects of misoprostol. A total of 16 dust mite- allergic patients received misoprostol (200 μg) or placebo and then had skin testing on 2 different days. The immediate- and late-phase skin response was monitored for 6 h. Skin biopsy was obtained from 5 selected donors at 5 h. In vitro studies included the effect of misoprostol on eosinophil chemotaxis, eosinophil survival, basophil histamine release, and cytokine production by lymphocytes. All subjects developed an immediate wheal reaction and a late- phase induration in response to dust mite allergens after taking placebo. Misoprostol selectively inhibited the late- but not the immediate-phase response (p < 0.05). Histologic studies revealed a trend toward a reduced number of inflammatory cells in the skin dermis after misoprostol treatment. Misoprostol significantly (p < 0.05) inhibited eosinophil chemotaxis and the production of granulocyte-macrophage colony-stimulating factor by lymphocytes at concentrations ≥ 10-8 M. However, at significantly lower concentrations (≥ 10-12 M) misoprostol blocked cytokine-stimulated eosinophil survival. Thus, misoprostol has potent antiallergic effects and blocks the cutaneous late-phase allergic inflammation.

Original languageEnglish (US)
Pages (from-to)1066-1070
Number of pages5
JournalAmerican Review of Respiratory Disease
Volume148
Issue number4
StatePublished - 1993

Fingerprint

Misoprostol
Prostaglandins E
Placebos
Antigens
Skin
Eosinophils
Anti-Allergic Agents
Mites
Chemotaxis
Dust
Allergens
Lymphocytes
Cytokines
Inhibition (Psychology)
Basophils
Histamine Release
Granulocyte-Macrophage Colony-Stimulating Factor
Dermis
Hypersensitivity
Cell Count

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog : Results of a double- blind, placebo-controlled randomized study. / Alam, R.; Dejarnatt, A.; Stafford, S.; Forsythe, P. A.; Kumar, D.; Grant, J. A.

In: American Review of Respiratory Disease, Vol. 148, No. 4, 1993, p. 1066-1070.

Research output: Contribution to journalArticle

@article{6773d5a612e4466ab189527a1ae90df1,
title = "Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog: Results of a double- blind, placebo-controlled randomized study",
abstract = "The objective of this study was to investigate the effect of misoprostol on allergen-induced cutaneous immediate- and late-phase allergic reactions in a double-blind placebo-controlled randomized study. We also studied the mechanism of antiallergic effects of misoprostol. A total of 16 dust mite- allergic patients received misoprostol (200 μg) or placebo and then had skin testing on 2 different days. The immediate- and late-phase skin response was monitored for 6 h. Skin biopsy was obtained from 5 selected donors at 5 h. In vitro studies included the effect of misoprostol on eosinophil chemotaxis, eosinophil survival, basophil histamine release, and cytokine production by lymphocytes. All subjects developed an immediate wheal reaction and a late- phase induration in response to dust mite allergens after taking placebo. Misoprostol selectively inhibited the late- but not the immediate-phase response (p < 0.05). Histologic studies revealed a trend toward a reduced number of inflammatory cells in the skin dermis after misoprostol treatment. Misoprostol significantly (p < 0.05) inhibited eosinophil chemotaxis and the production of granulocyte-macrophage colony-stimulating factor by lymphocytes at concentrations ≥ 10-8 M. However, at significantly lower concentrations (≥ 10-12 M) misoprostol blocked cytokine-stimulated eosinophil survival. Thus, misoprostol has potent antiallergic effects and blocks the cutaneous late-phase allergic inflammation.",
author = "R. Alam and A. Dejarnatt and S. Stafford and Forsythe, {P. A.} and D. Kumar and Grant, {J. A.}",
year = "1993",
language = "English (US)",
volume = "148",
pages = "1066--1070",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "4",

}

TY - JOUR

T1 - Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog

T2 - Results of a double- blind, placebo-controlled randomized study

AU - Alam, R.

AU - Dejarnatt, A.

AU - Stafford, S.

AU - Forsythe, P. A.

AU - Kumar, D.

AU - Grant, J. A.

PY - 1993

Y1 - 1993

N2 - The objective of this study was to investigate the effect of misoprostol on allergen-induced cutaneous immediate- and late-phase allergic reactions in a double-blind placebo-controlled randomized study. We also studied the mechanism of antiallergic effects of misoprostol. A total of 16 dust mite- allergic patients received misoprostol (200 μg) or placebo and then had skin testing on 2 different days. The immediate- and late-phase skin response was monitored for 6 h. Skin biopsy was obtained from 5 selected donors at 5 h. In vitro studies included the effect of misoprostol on eosinophil chemotaxis, eosinophil survival, basophil histamine release, and cytokine production by lymphocytes. All subjects developed an immediate wheal reaction and a late- phase induration in response to dust mite allergens after taking placebo. Misoprostol selectively inhibited the late- but not the immediate-phase response (p < 0.05). Histologic studies revealed a trend toward a reduced number of inflammatory cells in the skin dermis after misoprostol treatment. Misoprostol significantly (p < 0.05) inhibited eosinophil chemotaxis and the production of granulocyte-macrophage colony-stimulating factor by lymphocytes at concentrations ≥ 10-8 M. However, at significantly lower concentrations (≥ 10-12 M) misoprostol blocked cytokine-stimulated eosinophil survival. Thus, misoprostol has potent antiallergic effects and blocks the cutaneous late-phase allergic inflammation.

AB - The objective of this study was to investigate the effect of misoprostol on allergen-induced cutaneous immediate- and late-phase allergic reactions in a double-blind placebo-controlled randomized study. We also studied the mechanism of antiallergic effects of misoprostol. A total of 16 dust mite- allergic patients received misoprostol (200 μg) or placebo and then had skin testing on 2 different days. The immediate- and late-phase skin response was monitored for 6 h. Skin biopsy was obtained from 5 selected donors at 5 h. In vitro studies included the effect of misoprostol on eosinophil chemotaxis, eosinophil survival, basophil histamine release, and cytokine production by lymphocytes. All subjects developed an immediate wheal reaction and a late- phase induration in response to dust mite allergens after taking placebo. Misoprostol selectively inhibited the late- but not the immediate-phase response (p < 0.05). Histologic studies revealed a trend toward a reduced number of inflammatory cells in the skin dermis after misoprostol treatment. Misoprostol significantly (p < 0.05) inhibited eosinophil chemotaxis and the production of granulocyte-macrophage colony-stimulating factor by lymphocytes at concentrations ≥ 10-8 M. However, at significantly lower concentrations (≥ 10-12 M) misoprostol blocked cytokine-stimulated eosinophil survival. Thus, misoprostol has potent antiallergic effects and blocks the cutaneous late-phase allergic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=0027493209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027493209&partnerID=8YFLogxK

M3 - Article

VL - 148

SP - 1066

EP - 1070

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 4

ER -